hepatitis c

National Institute of Diabetes and Digestive and Kidney Diseases

State Medicaid programs – including Rhode Island – fail to provide enough access to cures for hepatitis C. That’s the conclusion of a new report from Harvard Law School’s Center for Health Law and Policy Innovation and the National Viral Hepatitis Roundtable. The authors say restricting treatment is illegal.

Forum: Seizing the Moment to End HepC

Oct 31, 2016
FORUM Seizing the Moment to End HepC
Aaron Read

Seizing the Moment to End Hepatitis C:
A Discussion with Experts and Advocates

WATCH THE ARCHIVED VIDEO WEBCAST HERE

Your Weekly Briefing: Health In Rhode Island

Aug 16, 2016
Kristin Gourlay / RIPR

Here's what's happening in health in Rhode Island. (Note: Your Weekly Briefing will be on vacation next week.)

New Report Finds Hep C Epidemic In Rhode Island

Aug 11, 2016
Kristin Gourlay / RIPR

For the first time, Rhode Island has one of the most complete pictures of the extent of the hepatitis C epidemic. More people are infected, and more are dying from the viral disease than previously known, finds a new study. But  more people are also getting treated – and cured.

Your Weekly Briefing: Health In Rhode Island

Aug 9, 2016
Kristin Gourlay / RIPR

Here's what's happening in health in Rhode Island.

  • Eliminate Hep C in RI? Brown researchers project more treatment could reduce hepatitis C by 90% in Rhode Island by 2030.

Your Weekly Briefing: Health In Rhode Island

Aug 2, 2016

Here's what's happening in health in Rhode Island:

RI Medicaid To Revisit Hepatitis C Drug Access Policy

May 4, 2016
Gilead Sciences

Rhode Island Medicaid is revisiting its policy for determining who receives pricey hepatitis C drugs. Current policy limits who gets treated and when, but those restrictions could be loosened.

Second State Sued Over Hepatitis C Medication Access

Feb 19, 2016
From the Annals of Internal Medicine article: Restrictions for Medicaid Reimbursement of Sofosbuvir for the Treatment of Hepatitis C Virus Infection in the United States / Authors: Soumitri Barua; Robert Greenwald, JD; Jason Grebely, PhD; Gregory J. Dore, MBBS, PhD; Tracy Swan; and Lynn E. Taylor, MD

Medicaid patients in Washington state (a similar suit is underway in Indiana) have sued the state's Medicaid agency claiming they were denied treatment for hepatitis C because of the high cost of the drugs. Litigation director Kevin Costello with the Harvard Center for Health Law and Policy Innovation says his organization has joined the lawsuit.

Medicaid May Go Too Far Restricting Hep C Meds

Nov 9, 2015
Gilead Sciences

  Federal officials say state Medicaid agencies may be going too far when it comes to restricting access to new hepatitis C drugs. Rhode Island, like many states, requires Medicaid patients to meet a list of criteria before doctors can prescribe them the new medications. But those criteria may be too restrictive.

RI Medicaid Denied 65% Of Requests For Hepatitis C Drugs

Aug 27, 2015
From the Annals of Internal Medicine article: Restrictions for Medicaid Reimbursement of Sofosbuvir for the Treatment of Hepatitis C Virus Infection in the United States / Authors: Soumitri Barua; Robert Greenwald, JD; Jason Grebely, PhD; Gregory J. Dore, MBBS, PhD; Tracy Swan; and Lynn E. Taylor, MD

Hepatitis C may not take as big of a chunk out of the state’s Medicaid budget as previously projected. One reason? A majority of patients who requested treatment have been denied.

On World Hepatitis Day, Taking Stock Of Progress

Jul 27, 2015
World Hepatitis Alliance

Tuesday, July 28th, 2015 marks the 5th annual World Hepatitis Day, a global awareness-raising event launched by the World Hepatitis Alliance, in concert with the World Health Organization.

On Saturday, August 1st, Providence marks the occasion with "C is for Cure: A WaterFire Lighting for RI Defeats Hep C."

Kristin Gourlay / RIPR

The future of health care for the poor, a review of Rhode Island’s criminal justice system, and politicking in Vermont…that’s part of the conversation this week on Political Roundtable. Rhode Island Public Radio’s Kristin Gourlay hosts; Ian Donnis is away. We're joined, as always, by URI political science professor Maureen Moakley and RIPR's political analyst Scott MacKay.

What We're Talking About When We Talk About Value

Jun 2, 2015

NPR's All Things Considered host Audie Cornish interviewed a prominent cancer doctor Monday about his public criticism of the high cost of cancer drugs.

Gilead Sciences

Experts on hepatitis C will present to lawmakers next Tuesday about the disease and how to prevent its spread in the Ocean State. Their presentation comes as state officials look for ways to pay for the growing cost of hepatitis C medications.

At The Crossroads: The Road Ahead For Hep C

Jan 16, 2015
Aaron Read / RIPR

Our months-long series about hepatitis C, "At the Crossroads: The Rise of Hepatitis C and the Fight to Stop It," has officially come to an end. We had a great public forum ("Hepatitis C: Cost, Cure, and Challenge") last night at Brown University, the audio from which is posted here, and some key takeaways from which I'll share, below.

    

Pages